ATNM (Actinium Pharmaceuticals) Risk Assessment

View and export this data going back to 2007. Start your Free Trial

What is Actinium Pharmaceuticals Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Actinium Pharmaceuticals is: No Data: Cannot be evaluated.

Competitive Comparison of Actinium Pharmaceuticals's Risk Assessment

For the Biotechnology subindustry, Actinium Pharmaceuticals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actinium Pharmaceuticals's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Actinium Pharmaceuticals (AMEX:ATNM) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Actinium Pharmaceuticals Risk Assessment Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinium Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (AMEX:ATNM) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

7AY1:Germany

Address

100 Park Avenue, 23rd Floor, New York, NY, USA, 10017

Website

https://www.actiniumpharma.com

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Executives

Sandesh Seth	director	300 E 93RD STREET, #20-B, NEW YORK NY 10128
Steve O'loughlin	officer: VP, Finance and Corporate Dev.	955 HARTMAN RUN ROAD, MORGANTOWN WV 26507
Dale L. Ludwig	officer: Chief Scientific Officer	21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028
Jeffrey W. Chell	director	521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767
Ajit Shetty	director	643 ZEEDIJK, KNOKKE C9 8300
Anil Kapur	officer: Chief Commercial Officer	275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Nitya G. Ray	officer: Executive Vice President	14 BAYBURY COURT, EAST HANOVER NJ 07936
Mark Stanley Berger	officer: Chief Medical Officer	140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Memorial Sloan-kettering Cancer Center	10 percent owner	1275 YORK AVE., NEW YORK NY 10065
Sergio Traversa	director	138 CANTERBURY LN, BLUE BELL PA 19422
C. David Nicholson,	director	103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Kaushik J Dave	director, officer: President and CEO	4 WATER STREET, EDISON NJ 08820
Richard I Steinhart	director	125 ELM STREET, NEW CANAAN CT 06840
Ahlb Holdings, Llc	10 percent owner	C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065
Actinium Holdings, Ltd.	10 percent owner	C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000